{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:21:28Z","timestamp":1787671288906,"version":"build-2736575974"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.maturitas.2026.109075","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T15:15:54Z","timestamp":1784992554000},"page":"109075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Consistency of efficacy and safety of elinzanetant for vasomotor symptoms and sleep disturbance associated with menopause across different populations: a review of the OASIS clinical trial program"],"prefix":"10.1016","volume":"212","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6707-3405","authenticated-orcid":false,"given":"JoAnn V.","family":"Pinkerton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Panay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella E.","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donal J.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Donders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio N.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Maki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Caetano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Haberland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaisa","family":"Laapas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lineke","family":"Zuurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.maturitas.2026.109075_bb0005","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/GME.0000000000001793","article-title":"Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden","volume":"28","author":"Nappi","year":"2021","journal-title":"Menopause"},{"issue":"4","key":"10.1016\/j.maturitas.2026.109075_bb0010","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1001\/jamainternmed.2014.8063","article-title":"Duration of menopausal vasomotor symptoms over the menopause transition","volume":"175","author":"Avis","year":"2015","journal-title":"JAMA Intern. Med."},{"issue":"3","key":"10.1016\/j.maturitas.2026.109075_bb0015","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ogc.2011.05.006","article-title":"Vasomotor symptoms and menopause: findings from the Study of Women's Health across the Nation","volume":"38","author":"Thurston","year":"2011","journal-title":"Obstet. Gynecol. Clin. N. Am."},{"issue":"6","key":"10.1016\/j.maturitas.2026.109075_bb0020","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1007\/s11325-024-03132-y","article-title":"Prevalence of poor sleep quality during menopause: a meta-analysis","volume":"28","author":"Jia","year":"2024","journal-title":"Sleep Breath."},{"issue":"10","key":"10.1016\/j.maturitas.2026.109075_bb0025","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1210\/jc.2016-2348","article-title":"Independent contributions of nocturnal hot flashes and sleep disturbance to depression in estrogen-deprived women","volume":"101","author":"Joffe","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2026.109075_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.562275","article-title":"Menopause and brain health: hormonal changes are only part of the story","volume":"11","author":"Maki","year":"2020","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.maturitas.2026.109075_bb0035","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017416","article-title":"Menopausal vasomotor symptoms and risk of incident cardiovascular disease events in SWAN","volume":"10","author":"Thurston","year":"2021","journal-title":"J. Am. Heart Assoc."},{"issue":"7","key":"10.1016\/j.maturitas.2026.109075_bb0040","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1161\/CIRCULATIONAHA.123.066491","article-title":"Trajectories of sleep over midlife and incident cardiovascular disease events in the Study of Women's Health Across the Nation","volume":"149","author":"Thurston","year":"2024","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.maturitas.2026.109075_bb0045","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/13697137.2016.1196047","article-title":"Revised global consensus statement on menopausal hormone therapy","volume":"19","author":"de Villiers","year":"2016","journal-title":"Climacteric"},{"issue":"7","key":"10.1016\/j.maturitas.2026.109075_bb0050","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of The North American Menopause Society","volume":"29","author":"\u201cThe 2022 Hormone Therapy Position Statement of The North American Menopause Society\u201d Advisory Panel","year":"2022","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.maturitas.2026.109075_bb0055","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/2053369116632439","article-title":"Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countries","volume":"22","author":"Constantine","year":"2016","journal-title":"Post Reprod. Health"},{"issue":"2","key":"10.1016\/j.maturitas.2026.109075_bb0060","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/bmjsrh-2023-202099","article-title":"A systematic review and critical appraisal of menopause guidelines","volume":"50","author":"Hemachandra","year":"2024","journal-title":"BMJ Sex Reprod. Health"},{"issue":"1","key":"10.1016\/j.maturitas.2026.109075_bb0065","article-title":"Long-term hormone therapy for perimenopausal and postmenopausal women","volume":"1","author":"Marjoribanks","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7","key":"10.1016\/j.maturitas.2026.109075_bb0070","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/09513590600842463","article-title":"The European menopause survey 2005: women\u2019s perceptions on the menopause and postmenopausal hormone therapy","volume":"22","author":"Genazzani","year":"2006","journal-title":"Gynecol. Endocrinol."},{"issue":"5","key":"10.1016\/j.maturitas.2026.109075_bb0075","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3109\/13697137.2015.1037267","article-title":"Discontinuation rates of menopausal hormone therapy among postmenopausal women in the post-WHI study era","volume":"18","author":"Kyvernitakis","year":"2015","journal-title":"Climacteric"},{"issue":"1","key":"10.1016\/j.maturitas.2026.109075_bb0080","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/13697137.2025.2530466","article-title":"Treatments in women experiencing natural menopause: a cohort study from the USA, the UK and Germany","volume":"29","author":"Saadedine","year":"2026","journal-title":"Climacteric"},{"issue":"3","key":"10.1016\/j.maturitas.2026.109075_bb0085","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12020-016-1072-9","article-title":"Efficacy of menopausal hormone therapy on sleep quality: systematic review and meta-analysis","volume":"55","author":"Cintron","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.maturitas.2026.109075_bb0090","author":"International Menopause Society"},{"key":"10.1016\/j.maturitas.2026.109075_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.maturitas.2025.108670","article-title":"PERCEIVE: a retrospective, qualitative interview-based study of the impact of vasomotor symptoms associated with menopause on the lives of individuals who are not suitable candidates for hormone therapy","volume":"200","author":"Hirschberg","year":"2025","journal-title":"Maturitas"},{"issue":"8","key":"10.1016\/j.maturitas.2026.109075_bb0100","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1016\/j.clbc.2024.08.017","article-title":"A dedicated menopausal after cancer clinic may improve adherence to endocrine therapy for breast cancer: a population based study","volume":"24","author":"Martin","year":"2024","journal-title":"Clin. Breast Cancer"},{"issue":"6","key":"10.1016\/j.maturitas.2026.109075_bb0105","doi-asserted-by":"crossref","first-page":"683","DOI":"10.6004\/jnccn.2021.7116","article-title":"Adjuvant hormone therapy-related hot flashes predict treatment discontinuation and worse breast cancer prognosis","volume":"20","author":"Zeng","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.maturitas.2026.109075_bb0110","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2019.909","article-title":"Non-hormonal strategies for managing menopausal symptoms in cancer survivors: an update","volume":"13","author":"Biglia","year":"2019","journal-title":"Ecancermedicalscience"},{"issue":"17","key":"10.1016\/j.maturitas.2026.109075_bb0115","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1001\/jama.295.17.2057","article-title":"Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis","volume":"295","author":"Nelson","year":"2006","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.maturitas.2026.109075_bb0120","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1056\/NEJMp1402080","article-title":"FDA approval of paroxetine for menopausal hot flushes","volume":"370","author":"Orleans","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2026.109075_bb0125","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/DHPS.S7634","article-title":"Antidepressant-associated sexual dysfunction: impact, effects, and treatment","volume":"2","author":"Higgins","year":"2010","journal-title":"Drug Healthc. Patient Saf."},{"issue":"6","key":"10.1016\/j.maturitas.2026.109075_bb0130","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/GME.0000000000002200","article-title":"The 2023 nonhormone therapy position statement of The North American Menopause Society","volume":"30","author":"The North American Menopause Society","year":"2023","journal-title":"Menopause"},{"issue":"4","key":"10.1016\/j.maturitas.2026.109075_bb0135","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/GME.0000000000002328","article-title":"Systematic review of neurokinin-3 receptor antagonists for the management of vasomotor symptoms of menopause","volume":"31","author":"Cieri-Hutcherson","year":"2024","journal-title":"Menopause"},{"issue":"4","key":"10.1016\/j.maturitas.2026.109075_bb0140","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/AOG.0000000000005114","article-title":"Safety of fezolinetant for vasomotor symptoms associated with menopause: a randomized controlled trial","volume":"141","author":"Neal-Perry","year":"2023","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.maturitas.2026.109075_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.maturitas.2024.108159","article-title":"Effect of fezolinetant on patient-reported quality-of-life outcomes: data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy","volume":"193","author":"Shapiro","year":"2025","journal-title":"Maturitas"},{"issue":"3","key":"10.1016\/j.maturitas.2026.109075_bb0150","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/AOG.0000000000005812","article-title":"Fezolinetant and elinzanetant therapy for menopausal women experiencing vasomotor symptoms: a systematic review and meta-analysis","volume":"145","author":"Menegaz de Almeida","year":"2025","journal-title":"Obstet. Gynecol."},{"issue":"16","key":"10.1016\/j.maturitas.2026.109075_bb0155","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/jama.2024.14618","article-title":"Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials","volume":"332","author":"Pinkerton","year":"2024","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.maturitas.2026.109075_bb0160","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa2415566","article-title":"Elinzanetant for vasomotor symptoms from endocrine therapy for breast cancer","volume":"393","author":"Cardoso","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2026.109075_bb0165","author":"Drug and Health Product Portal"},{"key":"10.1016\/j.maturitas.2026.109075_bb0170","author":"Food & Drug Administration"},{"key":"10.1016\/j.maturitas.2026.109075_bb0175","author":"Medicines and Healthcare products Regulatory Agency"},{"key":"10.1016\/j.maturitas.2026.109075_bb0180","author":"Therapeutic Goods Administration"},{"key":"10.1016\/j.maturitas.2026.109075_bb0185","author":"European Medicines Agency"},{"issue":"11","key":"10.1016\/j.maturitas.2026.109075_bb0190","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamainternmed.2025.4421","article-title":"Elinzanetant for the treatment of vasomotor symptoms associated with menopause: a phase 3 randomized clinical trial","volume":"185","author":"Panay","year":"2025","journal-title":"JAMA Intern. Med."},{"issue":"6","key":"10.1016\/j.maturitas.2026.109075_bb0195","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/GME.0000000000002350","article-title":"Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause","volume":"31","author":"Pinkerton","year":"2024","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2026.109075_bb0300","author":"HealthMeasures"},{"issue":"5","key":"10.1016\/j.maturitas.2026.109075_bb0370","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jval.2019.02.004","article-title":"PROMIS(\u00ae) adult health profiles: efficient short-form measures of seven health domains","volume":"22","author":"Cella","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.maturitas.2026.109075_bb0355","author":"European Medicines Agency"},{"issue":"10430","key":"10.1016\/j.maturitas.2026.109075_bb0200","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S0140-6736(23)02802-7","article-title":"Managing menopause after cancer","volume":"403","author":"Hickey","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.maturitas.2026.109075_bb0205","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70282","article-title":"The effects of elinzanetant on simulated driving performance in healthy women: a randomized phase I study","volume":"18","author":"Francke","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.maturitas.2026.109075_bb0210","article-title":"Correction: liver safety of the dual neurokinin-1\/-3 receptor antagonist elinzanetant","author":"Lewis","year":"2026","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.maturitas.2026.109075_bb0215","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/GME.0000000000002094","article-title":"Estimation of placebo effect in randomized placebo-controlled trials for moderate or severe vasomotor symptoms: a meta-analysis","volume":"30","author":"Zhou","year":"2023","journal-title":"Menopause"},{"issue":"6","key":"10.1016\/j.maturitas.2026.109075_bb0220","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/GME.0000000000002354","article-title":"Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2)","volume":"31","author":"Nappi","year":"2024","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2026.109075_bb0225","author":"European Commission"},{"key":"10.1016\/j.maturitas.2026.109075_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.maturitas.2025.108220","article-title":"Efficacy and safety of fezolinetant and elinzanetant for vasomotor symptoms in postmenopausal women: a systematic review and meta-analysis","volume":"195","author":"de Oliveira","year":"2025","journal-title":"Maturitas"},{"issue":"4","key":"10.1016\/j.maturitas.2026.109075_bb0235","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/01.JAA.0000000000000332","article-title":"Where do neurokinin receptor antagonists fit into management of menopausal vasomotor symptoms?","volume":"39","author":"Raji\u0107","year":"2026","journal-title":"Jaapa"},{"key":"10.1016\/j.maturitas.2026.109075_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2026.104812","article-title":"Neurokinin pathway antagonists for vasomotor symptoms in women with breast cancer: focus on elinzanetant and fezolinetant","volume":"88","author":"Pogoda","year":"2026","journal-title":"Breast"},{"issue":"7","key":"10.1016\/j.maturitas.2026.109075_bb0245","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the North American Menopause Society","volume":"29","author":"The North American Menopause Society Advisory Panel","year":"2022","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2026.109075_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejogrb.2025.114552","article-title":"Pharmacological treatments for menopausal vasomotor symptoms: a systematic review and Bayesian network meta-analysis of efficacy and safety","volume":"312","author":"Oliveira Amador","year":"2025","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.maturitas.2026.109075_bb0255","series-title":"The Menopause Society, Menopause Practice: A Clinician's Guide 6th edition","year":"2019"},{"issue":"6","key":"10.1016\/j.maturitas.2026.109075_bb0260","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1080\/13697137.2025.2585487","article-title":"Recommendations and key messages on women\u2019s midlife health and menopause","volume":"28","author":"Panay","year":"2025","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2026.109075_bb0265","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2147\/IJWH.S365808","article-title":"Vasomotor symptoms during menopause: a practical guide on current treatments and future perspectives","volume":"15","author":"Khan","year":"2023","journal-title":"Int. J. Women\u2019s Health"},{"key":"10.1016\/j.maturitas.2026.109075_bb0270","doi-asserted-by":"crossref","DOI":"10.1111\/1471-0528.70023","article-title":"Women's and health care professionals' experiences of discontinuing hormone replacement therapy (HRT): a systematic review","author":"Bunnewell","year":"2025","journal-title":"BJOG"},{"key":"10.1016\/j.maturitas.2026.109075_bb0275","series-title":"StatPearls","article-title":"Hot flashes","author":"Lugo","year":"2026"},{"issue":"2","key":"10.1016\/j.maturitas.2026.109075_bb0280","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10549-012-2114-5","article-title":"Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review","volume":"134","author":"Murphy","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.maturitas.2026.109075_bb0285","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.breast.2022.01.012","article-title":"Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: a systematic review","volume":"62","author":"Yussof","year":"2022","journal-title":"Breast"},{"issue":"27","key":"10.1016\/j.maturitas.2026.109075_bb0290","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1200\/JCO.2009.25.9655","article-title":"Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients","volume":"28","author":"Hershman","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.maturitas.2026.109075_bb0295","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1470-2045(11)70364-3","article-title":"Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial","volume":"13","author":"Mann","year":"2012","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.maturitas.2026.109075_bb0305","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/GME.0000000000002386","article-title":"Sleep disturbance associated with the menopause","volume":"31","author":"Maki","year":"2024","journal-title":"Menopause"},{"issue":"6","key":"10.1016\/j.maturitas.2026.109075_bb0310","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1097\/01.AOG.0000245449.97365.97","article-title":"Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial","volume":"108","author":"Soares","year":"2006","journal-title":"Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.maturitas.2026.109075_bb0315","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-045074","article-title":"Prescription medications for sleep disturbances among midlife women during 2 years of follow-up: a SWAN retrospective cohort study","volume":"11","author":"Solomon","year":"2021","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.maturitas.2026.109075_bb0320","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/GME.0000000000002209","article-title":"Efficacy and safety of lemborexant in midlife women with insomnia disorder","volume":"30","author":"Terauchi","year":"2023","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2026.109075_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.maturitas.2025.108821","article-title":"Efficacy and safety of daridorexant for the treatment of insomnia disorder in women of menopausal transition age: Insights from a randomized controlled trial","volume":"206","author":"Schaedel","year":"2026","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2026.109075_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.maturitas.2025.108782","article-title":"Fezolinetant compared with elinzanetant for the treatment of vasomotor symptoms associated with menopause: a matching-adjusted indirect comparison","volume":"205","author":"Stute","year":"2026","journal-title":"Maturitas"},{"issue":"1","key":"10.1016\/j.maturitas.2026.109075_bb0335","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.peptides.2008.05.016","article-title":"Menopause and the human hypothalamus: evidence for the role of kisspeptin\/neurokinin B neurons in the regulation of estrogen negative feedback","volume":"30","author":"Rance","year":"2009","journal-title":"Peptides"},{"issue":"3","key":"10.1016\/j.maturitas.2026.109075_bb0340","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.yfrne.2013.07.003","article-title":"Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes","volume":"34","author":"Rance","year":"2013","journal-title":"Front. Neuroendocrinol."},{"issue":"4","key":"10.1016\/j.maturitas.2026.109075_bb0345","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.cub.2019.01.022","article-title":"Kisspeptin neurons in the arcuate nucleus of the hypothalamus orchestrate circadian rhythms and metabolism","volume":"29","author":"Padilla","year":"2019","journal-title":"Curr. Biol."},{"key":"10.1016\/j.maturitas.2026.109075_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2021.170729","article-title":"Tachykinins amplify the action of capsaicin on central histaminergic neurons","volume":"150","author":"Sergeeva","year":"2022","journal-title":"Peptides"},{"issue":"6","key":"10.1016\/j.maturitas.2026.109075_bb0360","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s12325-024-02787-z","article-title":"Psychometric evaluation of the MENQOL instrument in women experiencing vasomotor symptoms associated with menopause","volume":"41","author":"Schultz","year":"2024","journal-title":"Adv. Ther."},{"issue":"6","key":"10.1016\/j.maturitas.2026.109075_bb0365","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/13697137.2023.2256658","article-title":"Global view of vasomotor symptoms and sleep disturbance in menopause: a systematic review","volume":"26","author":"Kingsberg","year":"2023","journal-title":"Climacteric"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512226002525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512226002525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:40:44Z","timestamp":1787668844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512226002525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":74,"alternative-id":["S0378512226002525"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2026.109075","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consistency of efficacy and safety of elinzanetant for vasomotor symptoms and sleep disturbance associated with menopause across different populations: a review of the OASIS clinical trial program","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2026.109075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109075"}}